We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Dried Blood Spot Sampling Used for HbA1c Measurement

By LabMedica International staff writers
Posted on 28 Sep 2015
The use of dried blood spot (DBS) sampling is an alternative to traditional venous blood collection, and particularly useful for people living in rural and remote areas, and for those who are infirm, house-bound or time-poor.

Glycated hemoglobin (HbA1c) is a biomarker that is fundamental for the diagnosis of diabetes and for monitoring glycemic control and traditionally its measurement depends on venipuncture, and on processing, transportation and storage of whole blood (WB) samples, which can be logistically challenging.

Scientists at The Australian National University (Canberra, Australia) collected venous and capillary blood samples from 115 adult participants. More...
After proper instruction, each participant punctured his/her own finger and collected capillary blood samples on pieces of a proprietary cellulose filter paper. Each filter paper was subsequently placed inside a breathable envelope, stored at room temperature, and processed on the same day (D0), four (D4), seven (D7) and fourteen (D14) days after collection.

HbA1c levels were measured in duplicates/triplicates in whole venous blood (WB), capillary blood (capDBS) and venous blood placed on the matrix paper (venDBS) and determined by a direct turbidimetric inhibition immunoassay that determines HbA1c as a percentage of total hemoglobin (%HbA1c). Assays were performed on an Indiko Plus (Thermo Fisher Scientific; Waltham, MA USA) automated biochemistry analyzer, and results were reported as %HbA1c National Glycohemoglobin Standardization Program (NGSP) values.

Eleven and 56 patients had type 1 and type 2 diabetes mellitus, respectively. Overall mean whole blood HbA1c levels were 6.22 ± 1.11%, 5.41 ± 0.35% for participants without diabetes, 7.80 ± 0.81% for volunteers with type 1 diabetes, and 6.61 ± 1.11% among individuals with type 2 diabetes. Mean ± SD capillary DBS (capDBS) levels of HbA1c were 6.62 ± 1.16% when measured on D0, 6.92 ± 1.32% on D4, 6.85 ± 1.29% on D7, and 6.62 ± 1.44% on D14. Venous DBS samples ranged from 6.72 ± 1.20% on D0 to 7.36 ± 1.47% on D7. Results from capDBS and venDBS showed high correlation and agreement to WB results, except for results from D14 samples.

The authors concluded the measurement of HbA1c from DBS samples provided results that were comparable to results from WB samples, if measured up to seven days after collection. Intra-assay coefficients of variation were low, results were in agreement with the gold-standard, and prediction intervals were clinically acceptable. The measurement of HbA1c through DBS sampling may be considered in situations where traditional venipuncture is not available. The study was published on July 8, 2015, in the journal BMC Clinical Pathology.

Related Links:

The Australian National University
Thermo Fisher Scientific 



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.